Zealand Pharma A/S

Good day and thank you for standing by. Welcome to the Zealand Pharma Interim Report Q3 2025 Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1, 1 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 1, 1 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Adam Lange, Investor Relations of Zeeland Pharma. Please go ahead.

Thank you, Operator, and thank you to everyone for joining us today to discuss Zeeland Pharma's results for the first nine months of 2025. You can find the related company announcement on our website at silanpharma.com. As described on slide two, we caution listeners that during this call, we will be making forward-looking statements that are subject to risks and uncertainties. Turning to slide three and today's agenda. With me today are the following members of Silan Pharma's management team. Adam Steensberg, President and Chief Executive Officer, Henriette Vennecke, Chief Financial Officer, and David Kendall, Chief Medical Officer. All speakers will be available for the subsequent Q&A session. Moving to slide four, I will now turn the call over to Adam Steensberg, President and CEO.

Thank you, Adam, and welcome, everyone. The third quarter of 2025 has been a quarter of strong execution and continued momentum in our partnership with Roche. We achieved a key milestone in the Petunia-type Phase II Supreme I trial in people with overweight and obesity, which put us well on track to report 42-week top-line data in the first half of 2026. We are also rapidly approaching data from several Phase III trials with cervical type in obesity, starting with top-line results from this 76-week synchronize one trial in the first half of 2026. Meanwhile, we are gearing up to outline our path towards becoming a generational biotech company at our capital market base next month. Moving to slide five. Two years ago, we laid out our vision to become a key player in the management of obesity through innovation that addressed one of the greatest healthcare challenges of our time, Central to this vision was developing an alternative to GD1-based therapies and to end the weight loss Olympics by focusing on the most important unmet medical need, a therapy that patients can and will accept to stay on. What excites me today is that Celan and Ross have the potential to lead in the next class of drugs for weight management. We are very confident in the profile of Petrientide as a potential best-in-class amylin analog supported by the clinical data to date and the last robust Phase II program currently underway. We are rapidly approaching Phase II data with Petrientide and Phase III obesity data with Cervidotide alongside an impressive Phase III MASH program that is well underway. I look forward to this next Catalyst with chapter and to sharing more from these programs at our upcoming capital market day where we will also discuss our intensified early stage efforts to build a generational biotech company. Let's turn to slide six. Six months have passed since we kicked off our alliance with Roche and I'm highly encouraged by the energy and commitment we have seen from both sides of the partnership. The agreement with Roche is more than just a deal. It's a shared commitment to redefine the future of weight management and to establish leadership in what could become the next foundational class of therapies. Last month, Sealand Pharma had the pleasure of welcoming Theresa Graham, CEO of Roche Pharmaceuticals, to our offices for an engaging fireside chat about exactly this. I was also pleased to see Roche, at their Pharma Day in September, convey to you their strong commitment to become a top three player in obesity. This is the reason why, through a highly competitive partnership process, we identified Roche as the ideal partner for C-Land Pharma and PetrinaSide. Turning to slide seven. Cervidotide is licensed to Boehringer Ingelheim, a leading family-owned biopharmaceutical company with a strong legacy in cardiovascular, renal, and metabolic diseases and a global presence across more than 130 markets. We're excited to see Boehringer Ingelheim potentially becoming the next major pharma company to enter the obesity market with a truly differentiated GF1-based therapy co-invented with Ceylon Pharma. We were also highly encouraged by their strong presence at Obesity Week in Atlanta last week. This leads me to slide eight. The scale and complexity of obesity make it a distinct and complex disease area in which we identified different segments. In the prescriber-driven segment, a key motivation for prescription is focused on comorbidity risk reduction, improving health outcomes, and relative weight loss. We believe Cervalutide has the potential to be uniquely positioned within this segment. The larger segment, however, is patient-driven. A significant focus here is personal weight loss goals and how individuals achieve them. The potential to deliver the weight loss that the vast majority of people with overweight and obesity desire, combined with an acceptable tolerability profile and and excellent patient experience, we believe that Trinitide is ideally positioned to lead in such a segment. I'm highly encouraged by the potential of both of our leading obesity programs, which holds potential to redefine the near-term future of weight management in key segments. And with that, let's move to slide nine as I turn over the call to our Chief Medical Officer, David Kendall, to discuss our R&D pipeline.